abaloparatide vs adalimumab
Side-by-side comparison of abaloparatide and adalimumab Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tymlos
Humira
Tymlos is a medicine to treat osteoporosis. It helps make your bones stronger and less likely to break.
Idacio is a medicine that blocks a protein called TNF. It is used to treat several diseases, including arthritis and Crohn's disease.
Tymlos treats osteoporosis in women after menopause and in men. It is for people who have a high chance of breaking a bone. This includes those who have already had a bone break due to osteoporosis or have other risk factors. It can also be used if other osteoporosis treatments did not work or could not be tolerated.
Idacio can help adults with rheumatoid arthritis by reducing joint pain and damage. It can also help children (2 years and older) with juvenile idiopathic arthritis. Idacio treats psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa and uveitis.
Tymlos is similar to a natural hormone in your body. It helps your body build new bone. This makes your bones stronger and less likely to break.
Idacio works by blocking a protein in your body called tumor necrosis factor (TNF). TNF can cause inflammation and damage in certain diseases. By blocking TNF, Idacio can reduce these symptoms.
- • High calcium in your urine
- • Feeling dizzy
- • Feeling sick to your stomach
- • Headache
- • Feeling your heart beat fast or irregularly
- • Infections (like colds or sinus infections)
- • Injection site reactions (redness, itching, pain, or swelling)
- • Headache
- • Rash
- Headache 4,180
- Feeling sick to your stomach 3,222
- Feeling dizzy 3,122
- Feeling tired 2,742
- Increased heart rate 2,139
- The medicine is not working 90,713
- Pain 49,062
- Joint pain 48,041
- Pain at the injection site 47,251
- Tiredness 39,113
Tymlos may increase the risk of bone cancer (osteosarcoma). You should not take this medicine if you have certain conditions that increase this risk. These include Paget's disease, bone cancer, radiation treatment to your bones, or certain hereditary disorders. If you have symptoms of feeling dizzy, palpitations, tachycardia, or nausea, you should sit or lie down.
Idacio can increase your risk of serious infections that could lead to hospitalization or death. Tell your doctor if you have any infections before starting Idacio. Idacio may also increase your risk of certain cancers, including lymphoma. Children and teens taking TNF blockers like Idacio have developed rare, aggressive cancers.
Tymlos is not for women who could get pregnant. It is not known if Tymlos can harm an unborn baby or pass into breast milk.
Tell your doctor if you are pregnant or plan to become pregnant. Idacio can cross the placenta and may affect your baby's immune system. Talk to your doctor about vaccines for your baby if you took Idacio during pregnancy.
Also Compare — Nearby Drugs
Compare adalimumab with
How to Read This abaloparatide vs adalimumab Comparison
abaloparatide is classified in the PTHrP Analog drug class, while adalimumab sits within the TNF-Alpha Inhibitor (Biologic) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, abaloparatide has 15,405 submissions while adalimumab has 274,180. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between abaloparatide and adalimumab — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.